DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
China · Delayed Price · Currency is CNY 16.15
+0.08 (0.50%)
Jun 18, 2026, 3:00 PM CST
SHA:603233 Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, SHA:603233 stock has a consensus rating of "Buy" and an average price target of ¥24.49. The average 1-year stock price forecast is 51.64% higher than the current stock price, while the lowest is ¥23.00 (+42.41%) and the highest is ¥26.70 (+65.33%).
Price Target: ¥24.49 (+51.64%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for SHA:603233 stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 10 | 10 | 11 |
Financial Forecast
Revenue This Year
29.97B
from 27.50B
Increased by 8.97%
Revenue Next Year
33.20B
from 29.97B
Increased by 10.79%
EPS This Year
1.29
from 1.07
Increased by 20.92%
EPS Next Year
1.46
from 1.29
Increased by 13.49%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 30.6B | ||
| Avg | 30.0B | ||
| Low | 29.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 11.2% | ||
| Avg | 9.0% | ||
| Low | 6.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.29 | ||
| Avg | 1.29 | ||
| Low | 1.29 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 20.9% | ||
| Avg | 20.9% | ||
| Low | 20.9% |